Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cizzle Biotechnology Holdings PLC on Friday announced a new collaboration into lung cancer testing with a US partner.
The London-based diagnostics developer has signed a head of terms to partner with a US full-service cancer reference laboratory CorePath Laboratories.
Shares in Cizzle were up 8.0% to 2.27 pence on Friday morning in London.
The strategic alliance will see Corepath use Cizzle's technology to develop an early-stage lung cancer test in the US. A royalty of 15% and other royalty sharing arrangements are proposed for Cizzle for any products and services based on CIZ1B in the US.
CorePath is a laboratory accredited by the Clinical Laboratory Improvement Amendments and College of American Pathologists.
‘The company's CIZ1B biomarker to detect early-stage lung cancer could represent a major breakthrough and we now have the opportunity to bring the benefits of this test to such an important market,’ said Executive Chair Allan Syms.
Copyright 2022 Alliance News Limited. All Rights Reserved.